Christine Muench1, Audrey Luo1, Katrin Charlet1,2, Jisoo Lee1, Daniel B Rosoff1, Hui Sun3, Samantha J Fede4, Jeesun Jung1, Reza Momenan4, Falk W Lohoff1. 1. Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 10 Center Drive (10CRC), Bethesda, MD, USA. 2. Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany. 3. Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 10 Center Drive (10CRC), Bethesda, MD, USA. 4. Clinical NeuroImaging Research Core, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 10 Center Drive (10CRC), Bethesda, MD, USA.
Abstract
AIMS: Differences in DNA methylation of the serotonin transporter gene (SLC6A4) have been shown to alter SLC6A4 expression and predict brain functions in healthy individuals. This study investigated the association between SLC6A4 promoter methylation and threat-related amygdala activation in individuals with alcohol dependence (AD). METHODS: Methylation of the SLC6A4 promoter region was assessed using peripheral blood DNA from 45 individuals with AD and 45 healthy controls (HCs). All participants completed an emotional face matching task in a 3-T magnetic resonance imaging (MRI) scanner. RESULTS: Results did not reveal any association between SLC6A4 promoter methylation variation and threat-related amygdala activation in HCs or individuals with AD. Furthermore, methylation in the promoter region of SLC6A4 did not significantly differ between the groups. CONCLUSIONS: Our results do not replicate a previous finding that increased methylation in the promoter region of SLC6A4 is associated with threat-related amygdala activation in healthy individuals and further show that there is no such association in individuals with AD. Given that the number of imaging epigenetics studies on SLC6A4 is very limited to date, these inconsistent results indicate that future research is needed to clarify its association with amygdala reactivity in both healthy and clinical populations. Medical Council on Alcohol and Oxford University Press 2019.
AIMS: Differences in DNA methylation of the serotonin transporter gene (SLC6A4) have been shown to alter SLC6A4 expression and predict brain functions in healthy individuals. This study investigated the association between SLC6A4 promoter methylation and threat-related amygdala activation in individuals with alcohol dependence (AD). METHODS: Methylation of the SLC6A4 promoter region was assessed using peripheral blood DNA from 45 individuals with AD and 45 healthy controls (HCs). All participants completed an emotional face matching task in a 3-T magnetic resonance imaging (MRI) scanner. RESULTS: Results did not reveal any association between SLC6A4 promoter methylation variation and threat-related amygdala activation in HCs or individuals with AD. Furthermore, methylation in the promoter region of SLC6A4 did not significantly differ between the groups. CONCLUSIONS: Our results do not replicate a previous finding that increased methylation in the promoter region of SLC6A4 is associated with threat-related amygdala activation in healthy individuals and further show that there is no such association in individuals with AD. Given that the number of imaging epigenetics studies on SLC6A4 is very limited to date, these inconsistent results indicate that future research is needed to clarify its association with amygdala reactivity in both healthy and clinical populations. Medical Council on Alcohol and Oxford University Press 2019.
Authors: Ahmad R Hariri; Alessandro Tessitore; Venkata S Mattay; Francesco Fera; Daniel R Weinberger Journal: Neuroimage Date: 2002-09 Impact factor: 6.556
Authors: M N Smolka; M Bühler; G Schumann; S Klein; X-Z Hu; M Moayer; A Zimmer; J Wrase; H Flor; K Mann; D F Braus; D Goldman; A Heinz Journal: Mol Psychiatry Date: 2007-01-09 Impact factor: 15.992
Authors: Lukas Pezawas; Andreas Meyer-Lindenberg; Emily M Drabant; Beth A Verchinski; Karen E Munoz; Bhaskar S Kolachana; Michael F Egan; Venkata S Mattay; Ahmad R Hariri; Daniel R Weinberger Journal: Nat Neurosci Date: 2005-05-08 Impact factor: 24.884
Authors: Robert A Philibert; Harinder Sandhu; Nancy Hollenbeck; Tracy Gunter; William Adams; Anup Madan Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2008-07-05 Impact factor: 3.568
Authors: Jana Wrase; Nicos Makris; Dieter F Braus; Karl Mann; Michael N Smolka; David N Kennedy; Verne S Caviness; Steven M Hodge; Lena Tang; Matthew Albaugh; David A Ziegler; Orin C Davis; Christian Kissling; Gunter Schumann; Hans C Breiter; Andreas Heinz Journal: Am J Psychiatry Date: 2008-07-01 Impact factor: 18.112